Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer in 185 countries. CA Cancer J Clin. 2018. DOI:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Gordon M, Tsai F, et al. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018;82(3):407–418.
   PubMed Web of Science ®Google Scholar
• Strauss J, Heery CR, Schlom J, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287–1295.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Martinez-Garcia M, Le Tourneau C, et al. First-in-human phase i study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/Anti-VEGF-A antibody, in adult patients with advanced solid tumors. Clin Cancer Res. 2018;24(7):1536–1545.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Zugmaier G, Klinger M, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017;102(4):e132.
   PubMed Web of Science ®Google Scholar
• Marhelava K, Pilch Z, Bajor M, et al. Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers (Basel). 2019;11(11):1756.
   Web of Science ®Google Scholar
• Kon E, Benhar I. Immune checkpoint inhibitor combinations: current efforts and important aspects for success. Drug Resist Updat. 2019;45:13–29.
   PubMed Web of Science ®Google Scholar
• Kvarnhammar AM, Veitonmäki N, Hägerbrand K, et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. J Immunother Cancer. 2019;7(1):103.
   PubMed Web of Science ®Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Herrera-Camacho I, et al. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649. Expert Opin Ther Pat. 2019;12:1–4.
   Google Scholar
• Li JF, Niu YY, Xing YL, et al. A novel bispecific c-MET/CTLA-4 antibody targeting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer. Biosci Rep. 2019;39(5):BSR20171278.
   PubMedGoogle Scholar
• Mittal D, Vijayan D, Neijssen J, et al. Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy. OncoImmunology. 2019;8(11):e1648171.
   PubMed Web of Science ®Google Scholar
• Dougall WC, Aguilera AR, Smyth MJ. Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity. Clin Transl Immunology. 2019;8(10):e0108.
   Web of Science ®Google Scholar
• Herrmann M, Krupka C, Deiser K, et al. Bifunctional PD-1× αCD3× αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood. 2018;132(23):2484–2494.
   PubMed Web of Science ®Google Scholar
• Koopmans I, Hendriks D, Samplonius DF, et al. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncoimmunology. 2018;7(8):e1466016.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yu M, Sun Z, et al. Generation and characterization of a bispecific antibody targeting both PD-1 and c-Met. Protein Pept Lett. 2017;24(12):1105–1112.
   Web of Science ®Google Scholar
• Kuchroo VK, Anderson AC, Brigham & women’s hospital, United States. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions. Worldwide patent WO2011159877A2. 2011 Dec 22.
   Google Scholar
• Li Y, Ludwig DL, Shen Y; Eli Lilly and Company and Zymeworks Inc, United States and Canada. Anti-PD-L1-anti-TIM-3 bispecific antibodies. United States patent US10279034. 2019 May 7.
   Google Scholar
• Herrera-Camacho I, Anaya-Ruiz M, Perez-Santos M, et al. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1. Expert Opin Ther Pat. 2019;29(8):587–593.
   PubMed Web of Science ®Google Scholar
• Loo K, Daud A. Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy. 2016;8(7):775–784.
   PubMed Web of Science ®Google Scholar
• Planes-Laine G, Rochigneux P, Bertucci F, et al. PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging-a literature review. Cancers (Basel). 2019;11(7):1033.
   Web of Science ®Google Scholar
• Yaghoubi N, Soltani A, Ghazvini K, et al. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312–318.
   PubMed Web of Science ®Google Scholar
• Wang L, Ma Q, Yao R, et al. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. Int Immunopharmacol. 2020;79:106088.
   PubMed Web of Science ®Google Scholar
• Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5–6):176.
   PubMedGoogle Scholar
• Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets. 2011;15(1):91–101.
   PubMed Web of Science ®Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Cebada J, et al. LAG-3 antagonists by cancer treatment: a patent review. Expert Opin Ther Pat. 2019;29(8):343–351.
   Web of Science ®Google Scholar
• Legat A, Maby-El Hajjami H, Baumgaertner P, et al. Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients—report of a phase I/IIa clinical trial. Clin Cancer Res. 2016;22(6):1330–1340.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs. 2013;31(3):707–713.
   PubMed Web of Science ®Google Scholar
• Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res. 2009;15(19):6225–6231.
   PubMed Web of Science ®Google Scholar
• Shah K, Smith D, La Motte-Mohs R et al. Macrogenics Inc., Unites States. PD-1 and LAG-3 binding molecules and methods of use thereof. United States patent US2019127467. 2019 May 2
   Google Scholar
• Codarri DL, Fischer J, Imhof-Jung S, et al., Switzerland. Bispecific antibodies specifically binding to PD1 and LAG3. United States patent US2018326054. 2018 Nov 15.
   Google Scholar
• Klein C, Schaefer W, Regula JT, et al. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods. 2019;154:21–31.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Presta LG, Ridgway JB, Genentech, United States. Method for making heteromultimeric polypeptides. United States patent US5821333. 1998 Oct 13.
   Google Scholar
• Status patent EP3606955. [cited 2020 Feb 15]. Available from: https://register.epo.org/application?number=EP18716573&lng=en&tab=doclist
   Google Scholar
• Status patent US2018326054. [cited 2020 Feb 15]. Available from: https://portal.uspto.gov/pair/view/BrowsePdfServlet?objectId=K41G17F4RXEAPX1&lang=DINO
   Google Scholar
• Khan S, Huang S, Ying H, et al. Merck Sharp & Dohme and Zymeworks Inc, United States. Anti-PD-1/LAG3 bispecific antibodies. Worldwide patent WO2019148412. 2019 Aug 08.
   Google Scholar
• Wang Z, Zheng Y, Li J, et al. Wuxi Biologics (China and Ireland). Novel bispecific PD-1/LAG-3 antibody molecules. Worldwide patent WO2019179422. 2019 Sep 26.
   Google Scholar
• Wu X, Gong S, Wu C. Shanghai Epimab Biotherapeutics, China. High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom. WO2019210848. 2019 Nov 07.
   Google Scholar